Suppr超能文献

精神分裂症中 NMDA 受体功能障碍动物模型中海马突触可塑性和认知的持久变化。

Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis.

机构信息

Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Universitätsstr. 150, MA 4/150, 44780 Bochum, Germany.

出版信息

Neuropharmacology. 2013 Nov;74:48-58. doi: 10.1016/j.neuropharm.2013.01.001. Epub 2013 Jan 31.

Abstract

It is postulated that disruptions of glutamatergic signalling may underlie the pathophysiology of psychosis and schizophrenia. A strong body of evidence indicates that antagonism of the N-methyl-d-aspartate receptor (NMDAR) leads to similar molecular, cellular, cognitive and behavioural changes in rodents and/or humans to those that have been identified to occur in psychosis. One of the main loci of change appears to comprise the hippocampus, raising the question as to whether changes in hippocampal glutamatergic transmission may drive changes in GABAergic and dopaminergic-mediated signalling in schizophreniform diseases. NMDAR antagonists such as MK801, PCP and ketamine all elicit similar psychosis-related effects, with MK801 inducing the most potent psychotomimetic reactions. Treatment with MK801 is associated with a loss of hippocampal synaptic plasticity, hippocampus-dependent learning and cognitive deficits. These findings have raised the question as to whether targeting the NMDA receptors or its modulators could prove an effective strategy in treatment of psychosis and schizophrenia. Specifically, the otherwise untreatable negative and cognitive symptoms of schizophrenia currently comprise the highest research priority. A single injection with MK801 has been used to emulate first-episode psychosis in animals. This treatment induces both psychosis-related acute effects but interestingly also persisting consequences, which might be more sensitive as indicators of drug efficacy. Here, we review the current status of the field with regard to the MK801 animal model of first-episode psychosis and its relevance for the glutamate hypothesis of schizophrenia. Furthermore, we argue that synaptic plasticity may be a better assay for assessing novel schizophrenia therapeutics than behavioural evaluation. This article is part of the Special Issue entitled 'Glutamate Receptor-Dependent Synaptic Plasticity'.

摘要

据推测,谷氨酸能信号的中断可能是精神病和精神分裂症病理生理学的基础。大量证据表明,N-甲基-D-天冬氨酸受体(NMDAR)拮抗剂在啮齿动物和/或人类中引起的分子、细胞、认知和行为变化与精神病中已确定发生的变化相似。变化的主要部位之一似乎包括海马体,这就提出了一个问题,即海马体谷氨酸能传递的变化是否会导致精神分裂样疾病中 GABA 能和多巴胺能介导的信号转导的变化。NMDAR 拮抗剂,如 MK801、PCP 和氯胺酮,都会引起类似的与精神病相关的效应,其中 MK801 引起的精神病样反应最强。MK801 的治疗与海马突触可塑性、海马依赖性学习和认知缺陷的丧失有关。这些发现提出了一个问题,即针对 NMDA 受体或其调节剂是否可以证明是治疗精神病和精神分裂症的有效策略。具体来说,目前精神分裂症中无法治疗的阴性和认知症状是最高的研究重点。MK801 的单次注射已被用于模拟动物的首发精神病。这种治疗会引起与精神病相关的急性效应,但有趣的是也会产生持续的后果,这些后果可能更敏感,是评估药物疗效的指标。在这里,我们回顾了关于 MK801 首发精神病动物模型及其与精神分裂症谷氨酸假说相关性的当前研究现状。此外,我们认为,与行为评估相比,突触可塑性可能是评估新型精神分裂症治疗药物的更好方法。本文是题为“谷氨酸受体依赖性突触可塑性”的特刊的一部分。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验